Dr. Turner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis St
Boston, MA 02115Phone+1 617-732-5500
Education & Training
Brigham and Women's HospitalResidency, Pathology-Anatomic and Clinical, 1991 - 1995
Case Western Reserve University School of MedicineClass of 1991
Certifications & Licensure
MA State Medical License 1994 - 2026
IL State Medical License 2001 - 2017
MI State Medical License 1996 - 2003
American Board of Pathology Anatomic Pathology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2005
Publications & Presentations
PubMed
- INTESTINAL EPITHELIAL-SPECIFIC OCCLUDIN DELETION WORSENS GUT PERMEABILITY AND SURVIVAL FOLLOWING SEPSIS.Tetsuya Yumoto, Takehiko Oami, Zhe Liang, Eileen M Burd, Mandy L Ford
Shock. 2025-04-01 - Tight junction regulation, intestinal permeability, and mucosal immunity in gastrointestinal health and disease.Kushal Saha, Yin Zhou, Jerrold R Turner
Current Opinion in Gastroenterology. 2025-01-01 - 1 citationsMyeloid beta-arrestin 2 depletion attenuates metabolic dysfunction-associated steatohepatitis via the metabolic reprogramming of macrophages.Xiaoli Wei, Dongqing Wu, Jing Li, Miaomiao Wu, Qianhui Li
Cell Metabolism. 2024-10-01
Press Mentions
Of the Most Mysterious Diseases Can It Be Prevented?March 13th, 2023- Six from HMS Elected 2020 AAAS FellowsNovember 24th, 2020
- Deficient Active Transport Activity in Healing Mucosa After Mild Gastric Epithelial DamageSeptember 12th, 2019
- Join now to see all
Grant Support
- Therapeutic targeting of protein interactions to reverse MLCK1-mediated intestinal barrier loss and ameliorate disease.BRIGHAM AND WOMEN'S HOSPITAL2005–2029
- Therapeutic targeting of protein interactions to reverse MLCK1-mediated intestinal barrier loss and ameliorate disease.BRIGHAM AND WOMEN'S HOSPITAL2005–2029
- Therapeutic targeting of protein interactions to reverse MLCK1-mediated intestinal barrier loss and ameliorate disease.BRIGHAM AND WOMEN'S HOSPITAL2005–2029
- Therapeutic targeting of protein interactions to reverse MLCK1-mediated intestinal barrier loss and ameliorate disease.BRIGHAM AND WOMEN'S HOSPITAL2005–2029
- Therapeutic targeting of protein interactions to reverse MLCK1-mediated intestinal barrier loss and ameliorate disease.BRIGHAM AND WOMEN'S HOSPITAL2005–2029
- Mechanisms and pathophysiologic impact of claudin-2 modulationBRIGHAM AND WOMEN'S HOSPITAL2001–2028
- Mechanisms and pathophysiologic impact of claudin-2 modulationBRIGHAM AND WOMEN'S HOSPITAL2001–2028
- Mechanisms and pathophysiologic impact of claudin-2 modulationBRIGHAM AND WOMEN'S HOSPITAL2001–2028
- Defining single-channel paracellular (tight junction) conductances using nanotechnologyBRIGHAM AND WOMEN'S HOSPITAL2023–2025
- Tissue And Cell Analysis CoreNational Institute Of Diabetes And Digestive And Kidney Diseases2011–2012
- Advanced Multi-Color Confocal And Frap-Sac MicroscopeNational Center For Research Resources2010
- Cell ImagingNational Institute Of Diabetes And Digestive And Kidney Diseases2006–2010
- Tight Junction Regulation By Myosin Light Chain KinaseNational Institute Of Diabetes And Digestive And Kidney Diseases2000
- Tight Junction Regulation By Myosin Light Chain KinaseNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2000
- Mechanisms Of Intestinal Tight Junction RegulationNational Institute Of Diabetes And Digestive And Kidney Diseases1996–2000
- Tight Junction Regulation In Intestinal EpitheliumNational Institute Of Diabetes And Digestive And Kidney Diseases1994–1996
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
